Daniel Raynor
Daniel Raynor is on the Argentum deal team for ReSearch Pharmaceutical Services, a clinical research organization acquired by Warburg Pincus in 2011.
What Daniel can write
The Argentum Group writes $3M to $30M checks, larger than 93% of firms in the atlas.
Bars: how many firms report each check band. Highlighted: The Argentum Group.Career
- ICN Pharmaceuticals, Inc. · Assistant to the CEO & Chairman
- Steinberg & Lyman · Senior Vice President, Corporate Finance
- Argentum · Managing PartnerNow
Companies founded
Investments named in public bios
Focus
Education
Also at The Argentum Group
Partners like Daniel
At firms with a similar stage, sector and check size.
Alert me when The Argentum Group is active
One email when Daniel's firm raises a fund, adds a partner or shows new activity.
Send Mode VC your deck
Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckQuestions
Who is Daniel Raynor?
Daniel Raynor is on the Argentum deal team for ReSearch Pharmaceutical Services, a clinical research organization acquired by Warburg Pincus in 2011.
How much does Daniel Raynor invest?
Daniel Raynor invests through The Argentum Group, which writes checks of $3M to $30M at series b.
How do I pitch Daniel Raynor?
A warm intro from a founder The Argentum Group backed works best. A short LinkedIn note with one line on traction is the next best route.
What did Daniel Raynor do before The Argentum Group?
Assistant to the CEO & Chairman at ICN Pharmaceuticals, Inc.; Senior Vice President, Corporate Finance at Steinberg & Lyman.
Last updated 2026-10-15. Is this you? Ask for a correction.